The Best Black Friday & Cyber Monday Sony A7III & A7RII Deals 2020 Reviewed by Consumer Articles

The Best Black Friday & Cyber Monday Sony A7III & A7RII Deals 2020 Reviewed by Consumer Articles

November 29, 2020 Off By administrator


Billionaire Israel Englander Pours Money Into 2 “Strong Buy” Stocks

Following the wild ride that was 2020, where does the market go from here? Major strides have been made in the COVID-19 vaccine race, yet the near-term picture remains unclear, blurred by the virus’ resurgence and the stimulus stalemate on Capitol Hill.In times like these, the investing greats can serve as a source of inspiration, namely billionaire Israel “Izzy” Englander.Who exactly is Englander? The legend, who started trading stocks when he was in high school, began his career interning at investment firm Oppenheimer, later going on to purchase a seat on the American Stock Exchange, where he would serve as a floor broker, trader and specialist.In 1989, along with Ronald Shear, Englander founded hedge fund Millennium Management. As evidence of his stellar track record, the guru took the $35 million the fund was started with and turned it into over $40 billion in assets under management. With his personal net worth clocking in at $7.2 billion, it’s no wonder Wall Street pays attention when Englander makes a move.Bearing this in mind, our focus shifted to Millenium’s most recent 13F filing, which discloses the stocks the fund snapped up in the third quarter. Locking in on two tickers in particular, TipRanks’ database revealed that both names score a “Strong Buy” analyst consensus. What’s more, the analyst community sees massive upside potential in store for each.G1 Therapeutics (GTHX)Bringing a deep understanding of the biology of cancer and extensive drug discovery experience to the table, G1 Therapeutics works to develop therapies that could potentially improve the lives of patients battling the deadly disease. Ahead of a key regulatory decision, the Street is pounding the table on this name.During the third quarter, Englander and Millennium picked up a new stake in GTHX. Pulling the trigger on 555,937 shares, the value of the holding comes in at $6,421,000.Turning to the analyst community, Needham’s Chad Messer tells clients that he has high hopes ahead of the February 15 PDUFA date for trilaciclib, its therapy designed to improve outcomes for cancer patients treated with chemotherapy. The therapy’s NDA was accepted in August for Priority Review based on results from three randomized clinical studies in small cell lung cancer (SCLC), with the FDA indicating that it doesn’t plan on holding an advisory committee (AdComm) meeting.As trilaciclib is the first CDK4/6 inhibitor to be used to treat chemo-induced bone marrow toxicity, Messer argues that the lack of an AdComm is “meaningful.” Expounding on this, he stated, “We believe this reflects the agency’s appreciation of the unmet need, comfort with the safety profile of the CDK4/6 class, and efficacy profile of trilaciclib.”GTHX will also focus on the inclusion of trilaciclib into NCCN guidelines. It should also be noted that a Phase 3 pivotal study evaluating the candidate in…

(Excerpt) To read the full article , click here
Image credit: source